The United States (US) Intracranial Aneurysm Market size is expected to reach $511.3 Million by 2030, rising at a market growth of 7% CAGR during the forecast period.
The intracranial aneurysm market in the United States is a dynamic and evolving sector driven by technological advancements. Intracranial aneurysms are abnormal bulges or ballooning in the walls of blood vessels within the brain, posing a significant risk of rupture and potentially life-threatening consequences such as hemorrhagic stroke. This condition affects a substantial portion of the population, with estimates suggesting that up to 6% of adults in the U.S. may have an intracranial aneurysm. However, many cases remain undiagnosed until a rupture occurs.
In recent years, there has been a growing trend towards minimally invasive techniques in the U.S. due to their reduced invasiveness, shorter recovery times, and lower risk of complications than traditional surgical approaches. This shift has been facilitated by advancements in imaging technology, catheterization techniques, and the development of novel devices specifically designed for endovascular procedures. Furthermore, ongoing research efforts to improve patient outcomes and reduce long-term complications have contributed to the expansion and diversification of the intracranial aneurysm market.
The COVID-19 pandemic has significantly impacted the intracranial aneurysm market in the U.S., disrupting healthcare systems, delaying elective procedures, and reshaping patient preferences and behaviors. In response to the pandemic, healthcare providers have implemented telemedicine solutions, remote monitoring technologies, and alternative care delivery models to ensure continuity of care while minimizing the risk of virus transmission.
The incidence of intracranial aneurysms in the United States has been on the rise in recent years, presenting a significant challenge in the management of neurological disorders. The aging population contributes to the increasing incidence of intracranial aneurysms. As people live longer, they are more likely to develop vascular diseases, including aneurysms. Additionally, advancements in medical imaging technology have led to more incidental detection of asymptomatic aneurysms during routine screenings for other conditions. This increased detection has contributed to a higher reported incidence of intracranial aneurysms.
According to the United States Census Bureau, in 2020, the older population in the United States numbered 55.8 million individuals, constituting 16.8% of the total population. Over a century, the older demographic has grown significantly, expanding by 50.9 million from 4.9 million (4.7% of the total U.S. population) in 1920 to 55.8 million (16.8%) in 2020. This demographic shift mirrors the increasing incidence of intracranial aneurysms within the intracranial aneurysm market in the U.S.
Furthermore, lifestyle factors such as smoking, hypertension, and drug abuse increase the risk of aneurysm formation and rupture. The prevalence of these risk factors in the population contributes to the overall increase in the incidence of intracranial aneurysms. Thus, the rising incidence of intracranial aneurysms in the United States underscores the importance of ongoing advancements in diagnosis, treatment, and management strategies to address this complex neurological challenge.
In recent years, there has been a concerning trend in the United States regarding the rising incidence of traumatic brain injuries (TBIs) within the intracranial aneurysm market. While the primary focus in the intracranial aneurysm market in the U.S. has traditionally been on managing and treating aneurysms, the increasing recognition of TBIs as a significant complication has prompted heightened attention and concern among healthcare professionals, researchers, and policymakers.
According to the Centers for Disease Control and Prevention, the incidence of TBIs has been steadily increasing in recent years, with approximately 214,110 TBI-related hospitalizations reported in 2020 and 69,473 TBI-related deaths in 2021 in the United States. Notably, individuals aged 75 years and older constitute the demographic with the highest numbers and rates of TBI-related hospitalizations and deaths, accounting for approximately 32% of hospitalizations and 28% of deaths related to TBIs. This trend reflects a significant concern within the intracranial aneurysm market in the U.S., as rising cases of TBIs among this population segment indicate an increased risk of associated complications, including intracranial aneurysms.
One of the key factors contributing to the rising incidence of TBIs in the intracranial aneurysm market is the complex interplay between aneurysm rupture and subsequent neurological damage. When an aneurysm ruptures, it can cause bleeding in the brain, leading to a cascade of events that may result in various types of TBIs, including contusions, hematomas, and diffuse axonal injuries. Moreover, the sudden increase in intracranial pressure following aneurysm rupture can exacerbate brain damage and significantly worsen patient outcomes.
As the population ages and the prevalence of these risk factors continues to rise, it is likely that the incidence of both aneurysm ruptures and associated TBIs also increases, further underscoring the importance of proactive management and prevention efforts. Hence, the rising incidence of traumatic brain injuries within the intracranial aneurysm market underscores the urgent need for proactive management strategies.
The intracranial aneurysm market in Japan is a dynamic landscape characterized by many companies striving to address the challenges posed by this complex medical condition. The intracranial aneurysm market in the United States is a dynamic landscape characterized by many companies striving to address the challenges posed by this complex medical condition. One prominent player in the U.S. intracranial aneurysm market is Medtronic plc. Medtronic offers a comprehensive portfolio of neurovascular devices and solutions aimed at treating intracranial aneurysms. Their product offerings include embolization coils, flow diversion devices, stents, and catheters used in minimally invasive procedures such as endovascular coiling and stent-assisted coiling. With a strong emphasis on innovation and clinical efficacy, Medtronic continues to be a leading provider of neurovascular technologies in the U.S.
Boston Scientific Corporation is also a key player in the U.S. intracranial aneurysm market. The company offers a range of neurovascular devices designed to treat intracranial aneurysms, including detachable coils, stents, and access catheters. Leveraging its expertise in minimally invasive medical technologies, Boston Scientific continues to introduce innovative solutions to improve patient outcomes and enhance procedural efficiency in treating intracranial aneurysms.
Another significant player in the U.S. intracranial aneurysm market is Stryker Corporation. Stryker's neurovascular division specializes in developing and manufacturing devices for treating various neurological conditions, including intracranial aneurysms. Their product portfolio comprises detachable coils, stents, flow diverters, and neurovascular access devices utilized by neuro-interventionalists to manage intracranial aneurysms. Stryker's commitment to advancing neurovascular care through innovation and clinical research underscores its prominent position in the industry.
Additionally, MicroVention, Inc., a subsidiary of Terumo Corporation, is also active in the U.S. intracranial aneurysm market. MicroVention specializes in the design and manufacturing of neurovascular devices for the treatment of intracranial aneurysms and other cerebrovascular conditions. Their product offerings include aneurysm coils, stents, and flow diversion devices utilized in endovascular procedures for aneurysm embolization and stabilization. With a commitment to advancing neuro interventional therapies, MicroVention continues to play a significant role in shaping the landscape of intracranial aneurysm treatment in the United States.
Penumbra, Inc. is another noteworthy participant in the U.S. intracranial aneurysm market. Penumbra specializes in the development of neurovascular devices for the treatment of various neurological disorders, including ischemic and hemorrhagic stroke. The company's product portfolio includes aspiration systems, thrombectomy devices, and embolization coils used in the endovascular treatment of intracranial aneurysms. Penumbra's focus on innovation and clinical collaboration has solidified its position as a trusted provider of neurovascular solutions in the U.S. Thus, the intracranial aneurysm market in the U.S. is characterized by several key players offering a diverse range of neurovascular devices and solutions.
By End-use
By Type
Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
Unique Offerings 